Australia markets close in 2 hours 41 minutes

Zealand Pharma A/S (22Z.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
92.00+4.20 (+4.78%)
At close: 07:21PM CET
Full screen
Previous close87.80
Open86.50
Bid90.80 x 200000
Ask92.00 x 388000
Day's range86.45 - 94.25
52-week range27.40 - 95.55
Volume1,097
Avg. volume143
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Zealand Pharma Announces Financial Results for the Full Year 2023

    Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a solid financial position Positive results achieved for petrelintide in 6-week Phase 1 trial and clinical advancement of dapiglutide and petrelintide towards obesity data readouts in 2024Positive results announced in Boehringer Ingelheim Phase 2 clinical trials for survodutide in obesity and global Phase 3

  • Yahoo Finance Video

    Zealand Pharma, Gap, Freshpet: Trending Tickers

    Zealand Pharma (ZEAL.CO) stock skyrockets on positive results from a liver disease treatment trial. JPMorgan analysts upgrade retailer The Gap (GPS) to Neutral, raising the price target to $20. Pet food company Freshpet (FRPT) sees its stock jump after beating fourth-quarter earnings estimates and issuing strong sales guidance. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.

  • GlobeNewswire

    Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

    Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of treatment versus placebo in a Phase 2 trialSurvodutide, a novel